Metformin

Metformin is a biguanide, one of a class of antihyperglycemic compounds, and it is the most widely used oral medicine for type 2 diabetes ^[1][2]. It lowers elevated blood glucose without prompting extra insulin secretion, so on its own it rarely causes hypoglycemia and tends to be weight-neutral, qualities that helped make it a first-line therapy recommended by major diabetes and internal-medicine bodies ^[1]. Chemically it is a small, water-soluble molecule usually supplied as metformin hydrochloride ^[1].

The drug traces its origins to Galega officinalis, the French lilac or goat's rue, a plant used in traditional European medicine and later found to be rich in guanidine-related compounds that lower blood sugar ^[1]. The biguanide metformin was first described in the 1920s, but it was the French physician Jean Sterne who studied it in people during the 1950s and gave it the name Glucophage, meaning glucose eater ^[1]. It was introduced in France in 1957 and approved in the United States in 1994, and it has since become one of the most prescribed medicines in the world ^[1].

Metformin's main use is the long-term control of blood sugar in type 2 diabetes, often as the foundation on which other therapies are added ^[1][2]. It is also prescribed in polycystic ovary syndrome, where it can help restore ovulation and menstrual regularity, and it has moderate evidence for delaying the progression from prediabetes to diabetes ^[1][2]. Large observational studies have linked metformin use in people with diabetes to lower overall mortality and reduced rates of cancer and cardiovascular disease, which, together with its effects on cellular energy metabolism, has spurred interest in whether it might influence aging itself; reviews are cautious, suggesting it may improve healthspan more than extend maximum lifespan, and dedicated clinical trials on aging have been proposed ^[1].

Metformin is a prescription medicine in most countries and appears on the World Health Organization's Model List of Essential Medicines ^[1]. It is sold generically in immediate-release and extended-release tablets and in liquid form ^[1]. The most common problems are gastrointestinal, including diarrhea, nausea, and abdominal discomfort, particularly when starting or increasing the dose, and these are eased by gradual escalation ^[1]. Long-term use can lower vitamin B12 levels, so periodic monitoring is advised, and a rare but serious complication is lactic acidosis, seen chiefly in people with significant kidney impairment, which is why the drug is avoided when kidney function falls too low ^[1].

The most common effects are gastrointestinal, nausea, diarrhea, and cramping, which often ease over time or with the extended-release form; long-term use can lower vitamin B12. The rare but serious risk is lactic acidosis, seen chiefly with significant kidney impairment, dehydration, or heavy alcohol use. Prescription medicine.

Metformin combined with iodinated contrast media used in imaging procedures significantly increases the risk of lactic acidosis, particularly in patients with impaired renal function ^[27]; ^[28]. This is a pharmacokinetic interaction where contrast media impairs renal clearance of metformin, allowing accumulation to toxic levels. The risk applies to iodinated contrast agents and warrants withdrawal of metformin for 48 hours before and 48 hours after contrast exposure if renal function is reduced ^[29]. What remains unstudied are safe metformin re-dosing schedules in patients with borderline renal function, the risk profile with low-osmolarity versus older high-osmolarity contrast agents, and whether timing of metformin dose relative to contrast administration affects outcomes.

Checking a whole stack? Run it through interactions + stacks.

Metformin traces its lineage to Galega officinalis, the French lilac or goat's rue, a herb used in medieval Europe for symptoms now recognized as diabetes and later found to be rich in guanidine, a compound with glucose-lowering properties. The biguanide dimethylbiguanide itself was first synthesized in 1922 by the Irish chemists Emil Werner and James Bell, but it drew little attention while insulin dominated diabetes care. Its therapeutic potential was established in the 1950s by the French physician Jean Sterne, who studied the molecule clinically and gave it the trade name Glucophage, meaning "glucose eater," with his key report appearing in 1957.

Introduced in France that same year, metformin spread through Europe over the following decades but reached the United States market only in 1995 after regulatory review by the Food and Drug Administration. It has since become the most widely prescribed oral medication for type 2 diabetes worldwide and appears on the World Health Organization's List of Essential Medicines. In the twenty-first century it has drawn renewed scientific interest for its investigational effects on aging, culminating in proposals for the landmark TAME (Targeting Aging with Metformin) trial.

Metformin is widely regarded as one of the most valuable and dependable medications in modern medicine, earning a reputation as the first-line therapy for type 2 diabetes across international guidelines. Clinicians favor it because it lowers blood sugar effectively while rarely causing the low blood sugar or weight gain associated with several other agents, and it carries a long track record of safety spanning more than sixty years of clinical use. Beyond glucose control, it is valued in polycystic ovary syndrome and prediabetes, and observational data have linked its use to favorable outcomes in cardiovascular health and certain cancers, though these applications remain under active study.

Its low cost and broad availability have made it a mainstay of care around the globe. Interest in metformin as a potential geroprotective agent has grown considerably, with researchers examining whether its effects on cellular energy metabolism might slow features of aging itself. It is worth noting that the evidence for extending human lifespan remains preliminary and debated, and its most common drawback is transient gastrointestinal upset that often eases with slow dose titration or extended-release formulations.